ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU

Inclusion Criteria: * Patient is between 18 and 85 years of age * Patient/legal representative provides written informed consent * Patient is scheduled for a coronary or peripheral diagnostic or interventional procedure * Patient is able to undergo emergent vascular surgery if a complication related to the VCD necessitates such surgery * Patient has a 7F arterial puncture located in the common femoral artery * Target vessel has a lumen diameter ≥ 5 mm * Patient is willing and able to complete follow-up * Catheterization procedure is planned and elective Exclusion Criteria: * Arterial puncture in the femoral artery of both legs * Prior target artery closure with any closure device or closure with manual compression ≤ 30 days prior to the cardiac or peripheral catheterization procedure * Patients with a history of significant bleeding or with any known or documented bleeding disorders, such as Thrombocytopenia (with \< 100,000 platelet count), Von Willebrand's disease, anemia (Hgb \< 10 g/dL, Hct \< 30%), thrombasthenia, decreased fibrinogen (\< 200 mg/dL), and Factor V deficiency * Acute ST-elevation myocardial infarction ≤ 48 hours prior to the cardiac or peripheral catheterization procedure * Uncontrolled hypertension (BP ≥ 180/110 mmHg) * Heparinized patients with elevated pre-closure ACT level:\> 250 seconds with GP IIb/IIIa inhibitor \> 300 seconds no GP IIb/IIIa inhibitor * Patient is ineligible for in-lab catheterization lab introducer sheath removal * Concurrent participation in another investigational device or drug trial * Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) ≤ 24 hours prior to the cardiac or peripheral catheterization procedure * Angiomax (bivalirudin) or other thrombin-specific anticoagulants or low molecular weight heparin ≤ 24 hours prior to the cardiac or peripheral catheterization procedure * Evidence of a preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to start of femoral artery closure procedure * Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery * The targeted femoral artery is tortuous or requires an introducer sheath length \> 11 cm * Fluoroscopically visible calcium, atherosclerotic disease, or stent ≤ 1 cm of the puncture site that would interfere with the placement of the VCD's plug * Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture * Antegrade puncture * BMI \> 40 kg/m2 * Symptomatic leg ischemia in the target vessel limb including severe claudication (\< 50 meter) or weak/absent pulse * Targeted femoral artery diameter stenosis ≥ 50% * Pre-existing severe non-cardiac systemic disease or pre-existing terminal illness * Planned arterial access at the same access site ≤ 30 days following the femoral artery closure procedure * Patient has known allergy to any materials used in the VCD * Patient is known to require an extended hospitalization (e.g. patient is undergoing CABG surgery) * Pre-existing systemic or cutaneous infection * Prior or recent use of an intra-aortic balloon pump through the arterial access site * Cardiogenic shock (hemodynamic instability requiring intravenous medications or mechanical support) experienced during or immediately post-catheterization * Patient is unable to ambulate at baseline * Patient is known or suspected to be pregnant, or is lactating * Patient has already participated in this trial * Patient has known allergy to contrast medium * Patient is unavailable for follow-up * Any angiographic or clinical evidence that the investigator feels would place the patient at increased risk with the use of the VCD * Required simultaneous ipsilateral or contralateral venous puncture